Literature DB >> 3163739

Purification and characterization of the external envelope glycoprotein from two human immunodeficiency virus type 1 variants, HTLV-IIIB and HTLV-IIIRF.

S W Pyle1, G C Dubois, W G Robey, J W Bess, P J Fischinger, L O Arthur.   

Abstract

External envelope glycoprotein from cell membranes and culture media of H9 cells infected with human immunodeficiency virus type 1 (HIV-1) isolate HTLV-IIIRF was isolated by immunoaffinity chromatography and compared with similar materials isolated from another variant, HTLV-IIIB. Envelope glycoprotein from IIIB and IIIRF appears to be identical, whether isolated from infected cell membranes or culture media. The molecular size of the IIIRF external envelope glycoprotein was 110 kilodaltons, whereas the relative size of IIIB gp120 was 123 kilodaltons. Amino-terminal sequence analysis of purified external envelope glycoprotein isolated from infected cell membranes or culture fluids revealed identical single sequences for the first 20 amino acids for each variant. The sequences obtained for IIIB gp120 were identical to those reported for the BH10 clone of the IIIB isolate, and the sequences determined for IIIRF gp110 matched the amino acid sequence predicted for the HAT3 clone of the Haitian HIV isolate. The amino-terminal sequences of external envelope glycoproteins isolated from either HIV-1 variant corresponded to the sequence starting at the proposed proteolytic cleavage site for the processing of the signal peptide of gp160. Immunization with external envelope glycoprotein isolated from either of the two HIV-1 variants yielded goat antibodies that primarily precipitated the homologous antigen. Sequential immunization of a single goat with gp120 and then gp110 resulted in the generation of antibodies that precipitated external envelope glycoprotein from both variants.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3163739      PMCID: PMC253367     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  27 in total

1.  Amino- and carboxyl-terminal amino acid sequences of proteins coded by gag gene of murine leukemia virus.

Authors:  S Oroszlan; L E Henderson; J R Stephenson; T D Copeland; C W Long; J N Ihle; R V Gilden
Journal:  Proc Natl Acad Sci U S A       Date:  1978-03       Impact factor: 11.205

2.  Cleavage at aspartyl-prolyl bonds.

Authors: 
Journal:  Methods Enzymol       Date:  1977       Impact factor: 1.600

3.  Complete nucleotide sequence of the AIDS virus, HTLV-III.

Authors:  L Ratner; W Haseltine; R Patarca; K J Livak; B Starcich; S F Josephs; E R Doran; J A Rafalski; E A Whitehorn; K Baumeister
Journal:  Nature       Date:  1985 Jan 24-30       Impact factor: 49.962

Review 4.  Molecular organization of the AIDS retrovirus.

Authors:  A B Rabson; M A Martin
Journal:  Cell       Date:  1985-03       Impact factor: 41.582

5.  Major glycoprotein antigens that induce antibodies in AIDS patients are encoded by HTLV-III.

Authors:  J S Allan; J E Coligan; F Barin; M F McLane; J G Sodroski; C A Rosen; W A Haseltine; T H Lee; M Essex
Journal:  Science       Date:  1985-05-31       Impact factor: 47.728

6.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

7.  Elution of proteins from sodium dodecyl sulfate-polyacrylamide gels, removal of sodium dodecyl sulfate, and renaturation of enzymatic activity: results with sigma subunit of Escherichia coli RNA polymerase, wheat germ DNA topoisomerase, and other enzymes.

Authors:  D A Hager; R R Burgess
Journal:  Anal Biochem       Date:  1980-11-15       Impact factor: 3.365

8.  Characterization of envelope and core structural gene products of HTLV-III with sera from AIDS patients.

Authors:  W G Robey; B Safai; S Oroszlan; L O Arthur; M A Gonda; R C Gallo; P J Fischinger
Journal:  Science       Date:  1985-05-03       Impact factor: 47.728

9.  Purification of 120,000 dalton envelope glycoprotein from culture fluids of human immunodeficiency virus (HIV)-infected H9 cells.

Authors:  S W Pyle; J W Bess; W G Robey; P J Fischinger; R V Gilden; L O Arthur
Journal:  AIDS Res Hum Retroviruses       Date:  1987       Impact factor: 2.205

10.  Detection, isolation, and continuous production of cytopathic retroviruses (HTLV-III) from patients with AIDS and pre-AIDS.

Authors:  M Popovic; M G Sarngadharan; E Read; R C Gallo
Journal:  Science       Date:  1984-05-04       Impact factor: 47.728

View more
  6 in total

1.  Posttranslational modifications distinguish the envelope glycoprotein of the immunodeficiency disease-inducing feline leukemia virus retrovirus.

Authors:  M L Poss; J I Mullins; E A Hoover
Journal:  J Virol       Date:  1989-01       Impact factor: 5.103

2.  Expression of interleukin 2 receptors by monocytes from patients with acquired immunodeficiency syndrome and induction of monocyte interleukin 2 receptors by human immunodeficiency virus in vitro.

Authors:  J B Allen; N McCartney-Francis; P D Smith; G Simon; S Gartner; L M Wahl; M Popovic; S M Wahl
Journal:  J Clin Invest       Date:  1990-01       Impact factor: 14.808

3.  Determinants of human immunodeficiency virus type 1 envelope glycoprotein activation by soluble CD4 and monoclonal antibodies.

Authors:  N Sullivan; Y Sun; J Binley; J Lee; C F Barbas; P W Parren; D R Burton; J Sodroski
Journal:  J Virol       Date:  1998-08       Impact factor: 5.103

4.  Adenovirus-human immunodeficiency virus (HIV) envelope recombinant vaccines elicit high-titered HIV-neutralizing antibodies in the dog model.

Authors:  R J Natuk; P K Chanda; M D Lubeck; A R Davis; J Wilhelm; R Hjorth; M S Wade; B M Bhat; S Mizutani; S Lee
Journal:  Proc Natl Acad Sci U S A       Date:  1992-08-15       Impact factor: 11.205

5.  Purified envelope glycoproteins from human immunodeficiency virus type 1 variants induce individual, type-specific neutralizing antibodies.

Authors:  P L Nara; W G Robey; S W Pyle; W C Hatch; N M Dunlop; J W Bess; J C Kelliher; L O Arthur; P J Fischinger
Journal:  J Virol       Date:  1988-08       Impact factor: 5.103

6.  Effect of lysine to arginine mutagenesis in the V3 loop of HIV-1 gp120 on viral entry efficiency and neutralization.

Authors:  Birco Schwalbe; Michael Schreiber
Journal:  PLoS One       Date:  2015-03-18       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.